stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Net income
Erasca, Inc.'s net income for fiscal 2025 was −$124.5M, compared with −$161.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$287.2M. Over the past ten years it has ranged from −$242.8M (fiscal 2022) to $0.00 (fiscal 2017); the current reading is higher than 50% of that period. Erasca, Inc. ranks 555th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$124.5M | — |
| FY2024 | −$161.7M | — |
| FY2023 | −$125.0M | — |
| FY2022 | −$242.8M | — |
| FY2021 | −$122.8M | — |
| FY2020 | −$101.7M | — |
| FY2019 | −$12.0M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$44.1M | — |
| Mar 2026 | −$183.4M | — |
| Dec 2025 | −$29.1M | — |
| Sep 2025 | −$30.6M | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$242.8M
High $0.00
Ten-year median
−$123.7M
Current reading's percentile
50
Net income against peers
| Company | Net income |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $1.0B |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| TVTX Travere Therapeutics, Inc. compare | −$121.5M |
| MANE Veradermics Incorporated compare | −$136.4M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| ERAS Erasca, Inc. | −$287.2M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| CRSP CRISPR Therapeutics AG compare | −$456.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item